Inhibition of inflammatory pain and cough by a novel charged sodium channel blocker
Abstract
Many pain‐triggering nociceptor neurons express TRPV1 or TRPA1, cation‐selective channels with large pores that enable permeation of QX‐314, a cationic analogue of lidocaine. Co‐application of QX‐314 with TRPV1 or TRPA1 activators can silence nociceptors. In this study, we describe BW‐031, a novel more potent cationic sodium channel inhibitor, and test whether its application alone can inhibit pain associated with tissue inflammation and whether this strategy can also inhibit cough.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jun 21, 2021
- Source ID
- 10.1111/bph.15531
Entities
People
- Benjamin Doyle
- Bruce D. Levy
- Bruce P. Bean
- Clifford J. Woolf
- David A. Roberson
- Ivan Tochitsky
- Jaehoon Shim
- Jinbo Lee
- Louise Haste
- Masakazu Kotoda
- Nick Andrews
- Sebastien Talbot
- Sooyeon Jo
- Stephen M. Jordan
Organizations
- Boston Children's Hospital
- Harvard Medical School
- Labcorp Drug Development
- National Heart, Lung, and Blood Institute
- National Institute of Neurological Disorders and Stroke
- United States Department of Defense
- Université de Montréal